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Introduction
One of the most interesting developments in the field of drug and alcohol studies in recent years has been the emergence of New Psychoactive Substances (NPS). This phenomenon is something of a (rapidly) moving target however, in terms of what we know about NPS, how different countries have reacted to their emergence and indeed, what we even mean by the term. This chapter will explore definitions, prevalence and user motivations in order to tease out the broader picture of what characterises NPS use, such that it should warrant a chapter in and of itself in this collection. A new typology of NPS is also proposed here, which couples pharmacological effects with chemical classifications, to provide an underlying framework for this review.
Although prevalence of use of NPS remains low by comparison with both established illegal drugs such as cannabis and cocaine, and established legal drugs such as alcohol and tobacco, this chapter suggests that the significance of the interest generated by NPS relates to the rapidity of innovation in manufacturing and retail practices; the speed and scale of policy responses; and the relationship between the two, which was initially characterised by commentators as 'cat and mouse'. 1 The authors conclude here that the dynamic interaction between the NPS market and policy change can be better characterised as 'hare and hounds' in that legislative control has been a significant driving force in manufacturing and retail innovations.
Definitions
The emergence and evolution of the NPS issue parallels the emergence and evolution of the terminology used to describe the appearance of a cluster of psychoactive substances in recent years which, unusually for the drugs field, were identified as a potential global threat before a significant physical or social problem emerged. The roots of the NPS debate can be traced back to the 1970s and the development of the term 'designer drug', itself a somewhat imprecise term, used to characterise psychoactive substances that were 1 Another metaphor applied to the relationship between pharmacological entrepreneurship and NPS legislative control compares this dynamic with 'cutting off the hydra's head' where several more grow back in its place, eg. 'Drugs have been a problem for centuries but legal highs have turned them into a narcotics version of Lernaean Hydra' (http://www.telegraph.co.uk/men/active/mens-health/11310863/Why-the-problem-of-legalhighs-wont-go-away.html) 3 derivatives of controlled drugs and had been created to circumvent existing legal restrictions specifically for recreational purposes. Buchanan and Brown (1988) , who ascribe the coining of the term to a California pharmacologist called Henderson, identify four main categories of 'designer drugs': phenylethylamines (eg. MDMA), synthetic opioids, methaqualone derivatives and arylhexylamines (eg. phencyclidine or PCP also known as 'Angel Dust', perhaps the most highly publicised of the 1970s designer drugs in the United States). However, contrary to the implication that these substances were created by street chemists, in fact many of these 'designer drugs' were the offshoots or rejects of commercial pharmaceutical research and development and hence the details of their synthesis had already been published in professional and academic papers (see Brandt et al., 2014 for an overview of the development of NPS nomenclature and definitions). Whilst the term 'designer drugs' continued to be used throughout the 1980s and 90s, another term started to emerge -'legal highs' -which was an indication of the broadening array of herbal as well as synthetic substances available as pills, powders, liquids and vegetable matter that were being manufactured and sold to emulate the appearance and effects of existing recreational drugs and to evade legislative control. The shift in emphasis here was towards herbal, and therefore by implication 'natural', products ('herbal highs') in contrast to the 'synthetic' associations of 'designer drugs' (also known as 'research chemicals').
In terms of NPS specifically, the watershed moment came in 2008 when the manufacture of synthetic cannabinoids and substituted cathinones became an international concern. Such were the numbers of new psychoactive substances identified by forensic scientists around the world from 2008 onwards that the term Novel Psychoactive Substances (Dargan et al., 2013) or New Psychoactive Substances was coined (EMCDDA, 2007) . For example, the term was widely enough accepted in scientific circles that by 2009 the UK Advisory Council on the Misuse of Drugs (ACMD) established a "New Psychoactive Substances Working Group" to address concerns. 2 The definition utilised by the ACMD working group was: "Psychoactive drugs which are not prohibited by the United Nations Single Convention on Narcotic Drugs or by the Misuse of Drugs Act 1971, and which people in the UK are seeking for intoxicant use." (ACMD, 2011: 10 (ACPO, 2011: 19) . This emphasis on circumventing legislative control led Newcombe to suggest that 'legal highs', the term still favoured by the media and in everyday conversation, could more accurately be considered "legal loophole" drugs (Newcombe, 2012a Unsurprisingly, given the wide variations in definitions of NPS, the consequent identification and publication of NPS-related problems and mortality rates themselves have been contentious, highly publicised and highly politicised (King and Nutt, 2014; Goodair et al., 2014 However, as the NPS definition has evolved to include both legal and illegal drugs, so it has come to include "substances that are not necessarily new but which have recently been increasingly abused" (International Narcotics Control Board, 2013: 36) . This net-widening has meant that some of the broadest NPS definitions now include:
i. not particularly 'new' illicit drugs (eg. ketamine, GHB/GBL), and in some cases more traditional illicit drugs (eg. psilocybe, khat) whose recreational use has been increasingly noted in some dance club scenes from the 1990s onwards (Measham et al 2001) , and 7 including psilocybe and khat products that were sold from 'headshops' prior to their prohibition (2005 and 2014, respectively) in the UK);
ii. a merging of NPS with 'club drugs' or 'dance drugs' (notably ecstasy, cocaine and amphetamines);
iii. long standing uncontrolled psychoactive drugs (eg. nitrous oxide, 'poppers');
iv. medicines which are legally manufactured and prescribed, and which again only recently were recognised as having any recreational appeal. Although 'indirectly' psychoactive (intoxication effects are typically described as 'side effects'), these various medications and pharmaceuticals can also be obtained without prescription from online pharmacy websites, some of which also sell the more popular NPS. mephedrone 'watershed' in the UK discussed further below, with NPS relating as much to a new cultural phenomenon as to specific psychoactive drugs. In this way NPS could be characterised as a flexible collective noun more akin to terms such as 'dance drugs' or 'club drugs' (Coomber et al 2013) .
Some colloquial terms for groups of NPS have also been coined by researchers across the globe. The main examples include 'research chemicals' for synthetic NPS (notably hallucinogens); 'herbal highs' for plant-based NPS; 'spice', 'mamba', or 'herbal incense' for synthetic cannabinoids; 'bath salts' for stimulants (particularly for cathinones in North America); and 'smart drugs' or 'nootropics' for eugeroic stimulants (see Table 1 below).
To conclude, our assessment of the evolution of the terms and concepts which describe and 
Classifications of NPS -towards a new taxonomy
In order to review the evidence on NPS -and to design research studies -it is necessary to go beyond the sculpting of clear and precise definitions such as those discussed above, to a principled classification of NPS. Therefore, in this section, we briefly examine the available conceptual frameworks for categorising NPS -that is, models developed to organize and classify specific NPS into broader categories according to rules of inclusion and exclusion.
Whilst a variety of classification systems exist in the literature, few are widely accepted 9 across all disciplines and professional groups involved with NPS, and the constantly evolving nature of NPS means that they can rapidly become outdated. The most common four dimensions of extant classifications are: by source, by legal/medical status, by psychoactive effect (on the brain and mind), and by chemical group. We discuss these four dimensions below before presenting a new multi-level classification of NPS based on two of the most important dimensions.
Source classification
The source classification is relatively straightforward: NPS can be broadly divided into natural and synthetic drugs. Natural NPS can be sub-divided into plant-based drugs (eg.
salvia, peyote, amanita muscaria) and animal-derived drugs (eg. cane-toad skin excretions).
Plant-based drugs (or plant extracts) are an NPS category frequently used by researchers.
Synthetic NPS can be sub-divided into semi-synthetic drugs (production of which starts with a natural drug) and fully synthetic drugs (made without recourse to natural drugs). A third classification by source is 'electronic highs', though these are outside the scope of this chapter (Newcombe, 2012b) . Also, as noted above, some NPS products contain a mixture of natural and synthetic drugs: notably 'synthetic cannabis' products, which may contain minor plant-based drugs mixed with synthetic cannabinoids (Uchiyama et al, 2010) .
Legal classification
Another common way of classifying NPS is by their legal status, which derives from national legislation assigning controlled drugs to classes/schedules, with criminal penalties for possession and trafficking offences reflecting the level of legal categorisation. This system is not fixed but constantly evolves as new legislation to control emerging NPS is introduced, and as laws in different countries are amended to allow new or revised categorisations.
National legislation on drugs, typically enacted in Medicine Acts, also covers medical and non-medical aspects of NPS use and supply (notably regulations on prescribing and dispensing). International legislation derives from the United Nations (notably the three drugs conventions) and in Europe from the European Union (EU) Parliament.
Focusing on the UK, NPS are categorised by the Misuse of Drugs Act 1971 (MoDA) in two ways: by three classes (A to C) which determine the penalties for possession and trafficking offences (up to life imprisonment for trafficking class A drugs); and by five schedules (1 to 5) 10 which regulate prescribing and dispensing (the strictest being schedule 1, which means the drug has no recognised medical use). Over the 21 st century, a growing number of NPS and new/problematic medical drugs have been legally controlled in the UK by successive amendments to the MoDA (see Table 1 ). 5 13 headings 7 -these can be further divided into legal and illegal drugs according to national laws. It should be noted that there are many types and levels of chemical classification and the categories used in Table 2 are open to further refinement. 8 Table 2 presents the taxonomy of drugs considered to be NPS according to at least some of the many definitions discussed above, which cover both 'new' drugs and 'legal' drugs, as well as drugs available from High Street 'headshops', online websites and other sources in the case of drugs such as laughing gas, poppers, khat and magic mushrooms. The scheme can also be modified and tightened to focus on NPS by our earlier operational definition (at the levels of chemical group and specific drugs). Clearly, given that the effects of drugs vary widely by sub-types and consumption patterns (eg. route of use, dose, setting), some drugs or drug categories could arguably be classified under alternative headings. For instance, the entactogen family could be included under the class of hallucinogens or stimulants, because entactogens vary widely in their effects and when consumed in different ways. Similar considerations apply to cannabinoids Even so, our taxonomy provides a useful framework for understanding and discussing NPS and will be used to organise the evidence which follows.
7 Specific chemicals sold as NPS branded products are also given trade names by manufacturers and retailers but these are not used here. 8 Space constraints preclude a more detailed discussion here. More detailed definitions of these classes of drugs, covering their chemistry and psychopharmacology, can be found on such websites as Erowid and Wikipedia. 
Trends in NPS production, supply and use
This section provides a brief overview of the main evidence concerning the development of NPS markets, including trends in production, distribution, availability, prevalence of use and consumption.
The challenges of defining and measuring drug use in general have been widely discussed elsewhere in this collection, and in relation specifically to NPS here. These ongoing challenges make estimating the prevalence of use -across drugs and population groupseven more complex. Moreover, allowing for the usual caveats for drug prevalence research 
Global NPS use
The World Drug Report (UNODC 2014: 51) has reported that NPS use is now "a truly global NPS included cannabinoids (29%), phenethlyamines (21%), cathinones (15%), tryptamines (8%), plant-based drugs (6%), piperazines (4%), arylcyclohexylamines (3%), aminoindanes (1%), and other NPS groups (11%).
The Global Drug Survey (GDS) accesses predominantly young adults through a range of general and specialist media websites such as The Guardian, Fox News and Mixmag. The 2013 GDS was based on a self selecting convenience sample of 78,800 people . Across the 18 countries with sample sizes of over 600 (average sample size: 4,000), 12% reported having used NPS/'legal highs' in the last year (using a broad definition of NPS which includes longstanding and non synthetic psychoactive substances including nitrous oxide and salvia) and 22% reported having bought drugs online. Of the ten types of NPS use reported, last year use of nitrous oxide was the most common (6%), reported by 14 countries and ranging from 1% in Portugal to 27% in the Netherlands. The other two most popular NPS were salvia and synthetic cannabinoids, with national rates of use ranging from 1% to 10%. The report on the December 2014 GDS noted that there was a substantial drop in last year NPS use to 7% . Among the 11 countries with over 1,500
respondents, last year use of NPS varied from below 10% in nine countries to 12% in the UK.
Overall, the most commonly reported 'research chemicals and legal highs' were synthetic cannabinoids: 2% reporting having used them in the last year.
A review of the literature on the epidemiology of NPS use by Sumnall and colleagues concluded that aside from mephedrone, salvia divinorum and SCRAs "most other NPS appear not to have made a significant impact on the drug market with respect to use preference … [and] remain infrequent choices" (2013: 99). They note that "most data on NPS epidemiology comes from (small) convenience samples", which produce findings with limitations given that "such data can only reveal drug use behaviours in the respondents surveyed, and cannot easily be generalized beyond the study " (2013: 99 (Johnston et al., 2014b) . The MtF surveys of over 40,000
secondary school students and several thousand college students and young adults aged 19
to 28 years has reported the prevalence of last year use of three itemized NPS in recent years (see Table 3 ) (Johnston et al., 2014a,b) . However, it is likely that drugs classified as NPS in some other studies or reporting systems are incorporated under general drug group headings in the MtF study -including hallucinogens (eg. NBOMe), inhalants (eg. nitrous oxide), tranquillizers (eg. phenazepam) and opioids (eg. MT-45). In 2014, levels of last year use of synthetic cannabinoids (also referred to as 'K2/Spice') ranged from over 3% among 8 th graders to almost 6% among 12 th graders. These represent significant drops from the previous year, and levels for all three grades have dropped steadily since 2012. Levels of last year use of salvia also dropped two to three-fold from 2010 to 2014 to below 2%, and last year use of synthetic stimulants ('bath salts') was reported by fewer than 1% of students in all grades in 2014. Levels of last year use of all three NPS have fallen fairly steadily across recent years for both groups, and to lower levels than those for school students by 2013 -3% or lower for cannabinoid use, and 1% or lower for use of salvia and stimulants.
Prevalence of NPS use across Europe
The Early Warning System run by EMCDDA (2015) Slovenia (from 7% to 13 %), Slovakia (from 7% to 13%), Spain (from 5% to 13%), France
(from 5% to 12%), and UK (from 2% to 10%). The biggest increase was in the UK, where the proportion of NPS users increased fivefold between the two surveys. and ex-prisoners also reported that synthetic cannabinoids are the most popular drug in UK prisons (Linnell et al, 2015) .
NPS availability and use in the UK
The 2013/14 annual report of the UK Forensic Early Warning System (FEWS) noted that "so far the Coalition Government has controlled over 350 NPS, by group or generic definitions, 21 including some not seen in the UK, under the 1971 Act" (FEWS, 2014: 4) . 9 The total number identified since 2011 was 31, including 10 cannabinoids, four tryptamines, three phenethlyamines, and three cathinones. Analysis of NPS samples collected by FEWS found that around nine out of ten were mixtures of either two (61%) or three (30%) active drug ingredients. In 2013/14, 3% of internet and 4% of headshop samples contained controlled NPS, compared to 16% and 64% in 2012/13. However, 88% of festival samples contained controlled drugs in 2013/14, a similar amount to 2012/13 (84%) (FEWS, 2014 ).
An NPS was the primary drug 10 of concern for 144 people in drug treatment in England in 2013/14 -just under 0.1% of all drug treatment clients (Public Health England, 2014).
However, separate statistics for mephedrone and GHB/GBL indicated that the number of NPS users in treatment had almost tripled over the last three years.
General household surveys
Annual general household surveys of drug use are conducted in all countries of the UK but due to space constraints, we focus here on prevalence surveys in England and Wales only (see UK Drug Focal Point, 2014, for a summary of NPS use across the UK). The annual Crime
Survey for England and Wales (CSEW) includes a general household survey of drug use among over 20,000 adults (Home Office, 2014) and is the most robust national data set on drug prevalence in the UK. Over the six years ending 2014/15, the CSEW has reported on the prevalence of use of seven types of NPS: mephedrone, spice, khat, BZP, GHB/GBL, nitrous oxide and salvia. Overall lifetime and last year use of mephedrone has declined steadily for both adults and young adults since it was controlled and national data was first collected in 2010, although it rose slightly in 2013/14 (see Table 4 ). 11 (Table 5) . Nitrous oxide was the second most commonly used drug by young adults in the UK after cannabis, and the third most commonly used drug by all adults after cannabis and cocaine. 12 The figures on last year use also show that mephedrone and salvia are the fifth and sixth most popular drugs among young adults (ecstasy is fourth). 161,000 to 205,000. By 2013/14, these numbers included 394,000 young adults who had ever used mephedrone and 117,000 young adults who had used mephedrone in the last year (Lader 2015) . 12 It can be extrapolated from these figures that the number of last year users of nitrous oxide in the UK climbed from over half a million in 2012/13 to nearly three quarters of a million in 2013/14. 
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Motivations and user groups
In this final section we draw together some of the evidence discussed above to piece together why the NPS phenomenon shot into the spotlight from 2008 onwards and what might be the motivations of users, which then sheds light on who are the key user groups.
Whilst many of the reasons for taking NPS are similar to the motivations for consuming a whole host of other psychoactive substances -legal, illegal or prescription; prohibited, controlled or licensed -it is only through an understanding of the inter relationship between established and 'new' psychoactive substances that we can more fully understand their appearance and appeal.
(1) Purity A key reason for the emergence of NPS relates to their relative purity, by comparison with established drugs across Europe in that particular historical period (Measham, 2013) . higher purity 'premium' product in the mid 2000s in the UK (Smith et al., 2009) . Conversely, forensic analyses of mephedrone showed that it was being sold at approximately 95% purity before legislative control in 2008 -10 (Miserez et al., 2014 . Whilst it could be argued that it was merely coincidence that the purity levels of the most popular established illegal stimulants were at their lowest point in decades at the very same time that mephedrone (a legal stimulant with not dissimilar effects to cocaine and ecstasy) first became a concern, studies with users endorse this connection. Interviews with mephedrone users before legislative control in the UK (Professional male, 34, 2009 From 2011 onwards both DIMS and UK forensic analyses suggest that the purity of cocaine and ecstasy increased again across Europe, with the MDMA content of seized ecstasy pills increasing five fold from 20mg to 100mg in the six year period 2008 (ACMD 2015 .
Conversely, after legislative control of substituted cathinones in 2010, forensic analyses of second generation NPS show that unlike the first generation NPS of high purity, these second generation NPS were of variable content and sometimes even illegal (Brandt et al., 2010) . The variable content, effects and legal status of these NPS were widely publicised, capitalised on by politicians and drugs prevention campaigns. This may have dampened some of the initial demand for NPS and resulted in a fall in NPS prevalence rates in annual surveys, including both the general household survey and convenience sample surveys of festival-goers (Measham, 2013) and club-goers (Wood et al., 2012a) . The rise and fall in self reported mephedrone use contrasts with the disillusionment and then reinforcement of ecstasy's appeal as the MDMA content of tablets rose to and surpassed their previous levels (Pidd, 2014) . So a key point here is that the appeal of NPS products when they first 25 appeared related to the purity and reliability of their contents relative to the purity and reliability of established illegal drugs, and the relationship between the two. 13 (2014) It should not be assumed that there was simple displacement from low purity Class A drugs to high purity legal NPS in 2008/9, however. Annual surveys conducted with club-goers at South London gay-friendly dance clubs from 2010 onwards have shown consistently high levels of self reported mephedrone use each year, with mephedrone becoming the drug most likely to be consumed on a night out and also these club-goers' favourite drug (Measham et al 2011a; Wood et al 2012b) . However, these surveys found no evidence of wholesale displacement from Class A drugs such as cocaine and ecstasy to NPS, but rather mephedrone appeared to have been added to existing drug-using repertoires and was being used as a supplement, a secondary drug, to 'top up' low purity Class As (Moore et al., 2013) . This is supported by the general population survey (Smith and Flatley, 2011) which reports that nine in ten mephedrone users reported having used other illegal drugs in the last year.
These various studies suggest, therefore, that purity was a particular appeal for users who were already experienced Class A drug users, such as club-goers. A further indicator of the elasticity of demand for mephedrone and its possible status as a 'topping up' drug relates to 13 There is some evidence that purity levels and accurate labelling is increasing again amongst third generation NPS products (FEWS 2014; ACMD 2015) .
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the fact that the price only rose to £20/25/gram after legislative control in 2010 and has stayed at that price since then. 14
(2) Availability
This has been a significant driver to NPS use: for the first time psychoactive drugs were widely, cheaply and legally available online, in specialist headshops, market stalls, festivals and (of increasing concern) at small independent convenience stores and petrol garages with variable retail practices (NPS Review Expert Panel, 2014) . However, as with purity, availability of NPS is also relative and usually gauged in comparison with the access and availability of illegal drugs. So for users who either could not access or did not want access to established drugs through street 'dealers', legal NPS hold an obvious appeal.
The DrugScope 2013 street drug trends survey, based on information from drugs workers at 25 agencies in mainland Britain, revealed that the main source of NPS was not internet websites but specialist 'headshops' and also non-specialist shops such as petrol stations, pet shops, takeaway food shops, newsagents, tobacconists, sex shops and market stalls. While few young people were coming forward to treatment services, outreach workers reported that some young people were at risk of serious health consequences, a finding confirmed in the qualitative study by Linnell and colleagues (2015) . Daly (2013) also reported that a snapshot survey carried out in Newcastle of 116 people (mainly teenagers aged [16] [17] found that, of those who had recently bought 'legal highs', 45 had purchased them from headshops, while 20 had bought them from a petrol station or takeaway food shop.
Availability of NPS appeals particularly to teenagers and novice users without established contact with illicit subcultures and illegal economies (evidenced in the disproportionate numbers of patients in their mid teens hospitalised for SC-related problems in the UK).
Others who may not be able to access illegal drugs through street dealers may be residents in rural areas without easy access to urban street markets and middle class professionals who were suddenly able to order NPS products online with a credit card and without the risks associated with purchasing illegal drugs such as being exploited by street dealers or caught by the police. The converse of this is that once mephedrone was banned self reported use fell (eg. Lader, 2015; Measham, 2013 suggesting that at least 14 Whilst it doubled in price compared with its legal price of £10/gram, it remains at about half the price per gram of MDMA and cocaine in the UK.
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in part, once availability plummeted, so did use. Furthermore, for those who continued to use controlled NPS, their use was likely to be more risky in terms of both physical and social harms due to greater variations in content and purity in unregulated markets combined with accessing criminal supply networks.
(3) Legality
If prevalence of NPS use falls in the years after legislative control, as indicated with falling mephedrone use in the UK general household survey discussed above (Lader 2015) , then perhaps this can be seen as evidence of a deterrent effect of banning drugs, as distinct from the impact of reduced availability resulting from the ban on legal sales? In general there is a weak evidence base on the deterrent value of criminal law. What we know from international comparative drug policy analyses (eg. EMCDDA, 2011c; Stevens, 2011) and regional times-series data (eg. Wood et al., 2012b) is that there appears to be little impact of drug policy change on drug use in a range of different jurisdictions.
Furthermore, in surveys and interviews, users themselves rarely prioritise legal status when discussing why, or indeed why not, to take illegal drugs (eg. Parker et al., 1998) . Research with users has found that more important reasons for taking or avoiding drugs include price, purity, availability, perceived pleasurable/unpleasant effects, curiosity and the wider social context to use (Norman et al., 2014; O'Brien et al., 2015) . Moreover, if, as discussed above, NPS users are more likely to be experienced drug users and take NPS along with illegal drugs in weekend polydrug repertoires, then the legal status of NPS in particular is of little relevance.
Where legal status has been found to result in a significant appeal for uncontrolled NPS has been for those who come into contact with drug testing, through employers, treatment services, the operation of motor vehicles, and the criminal justice system more generally.
For example, SCRAs have been found to hold a particular appeal amongst US professionals (Perrone et al., 2013) ; UK professionals (Sumnall et al., 2016) ; UK prisoners (Brown, 2014) ;
UK ex-offenders (Linnell et al 2015) and clients in treatment who are drug tested.
(4) Media
A fourth key driver to NPS use has been the media. Intense media scrutiny of NPS drugrelated deaths and NPS policy have led to a symbiotic relationship between press coverage, 28 policy makers and user demand for drugs (Forsyth, 2012; Measham et al., 2011b) . For NPS at least as much as for any other drug problem, there is a sharp contrast between the lack of information regarding short and long term effects of use, the spiralling numbers of psychoactive substances available and the burgeoning easy access both to information and to retailers themselves through the internet. Although not unique to NPS -the early internet was utilised when ecstasy gained popularity with 1990s dance club cultures 15 -it has been widely noted how pivotal the internet has been to the development of NPS (Forsyth, 2012; Schifano et al., 2010) , with NPS being considered the first group of drugs to be born out of the internet age. Indeed the internet has played a multi faceted role in relation to the development of NPS, from the facilitation of multi media news, research data collection and dissemination, dark and clear net retail outlets, to online user forums and virtual communities (Barratt et al 2014; O'Brien et al., 2015) .
Conclusion: From 'cat and mouse' to 'hare and hounds'
In answer to the question what is new about New Psychoactive Substances, it is the speed of innovation combined with the globalisation and virtualisation of drug markets and user groups that have together led to the essential 'newness' of the NPS phenomenon. However, within this innovation also lies another key feature of the NPS debate. The rapidity of NPS manufacturing and marketing innovations move in conjunction with the rapidity of policy developments. This relationship between pharmacological and policy developments was widely characterised in the early years as a 'cat and mouse' relationship (including by the authors elsewhere: Measham et al., 2010) , with NPS chemists and entrepreneurs ready to respond to each new piece of legislation. Having seen several generations of NPS and NPSrelated legislation now develop, one of the authors 16 has suggested that it is perhaps more accurate to characterise this relationship between NPS development and policy change as 'hare and hounds' rather than 'cat and mouse' because it is the speed of policy change which itself is the driving force behind the faster and faster pace of NPS innovations.
Without each set of generic controls of SCRA in the UK, for example, it is highly unlikely that 15 With ecstasy came the advent of ecstasy information and analysis forums and pill report sites eg. www.ecstasy.org. 16 Measham, F (2014) there would have been a further generation of SCRA development within such rapid succession of the previous one.
In conclusion, we see pockets of popularity and differentiated demand for NPS around the world, with legislative control impacting on purity, availability, price and appeal for some drugs in some areas, but persistent use by some others. Although prevalence of use of NPS remains low by comparison with established illegal drugs in most countries, the significance of the rise of 'legal highs' relates to the rapidity of innovation in this area and also the speed and scale of policy responses. In contrast to established illegal drugs, control regimes have been quick to respond to the perceived threat, the level of which has led to innovation and expansion of control regimes. Therefore rather than a 'consensus fracture' as we have seen in relation to established illegal drugs and the 'war on drugs' (Bewley- , global drug prohibition regimes have indicated their capacity for innovation, adaptation and cooperation, with a tightening of the drug policy ratchet and the blanket of prohibition being thrown wider (Stevens and Measham, 2014) . Indeed it is in the response to criticism of prohibition as a creaky structure ill fitted to tackling the emergent NPS problem, that we have seen a reinvigoration, expansion and U-turn away from more liberal regimes with the introduction of the current regime of analogue, generic and 'blanket ban' control measures from 2009 onwards, resulting in a new era for both pharmacological and policy developments.
